XML 48 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Cash flows from operating activities:      
Net loss $ (11,094)us-gaap_NetIncomeLoss $ (14,083)us-gaap_NetIncomeLoss $ (13,628)us-gaap_NetIncomeLoss
Adjustments required to reconcile net loss to net cash used in operating activities:      
Stock-based compensation 3,633us-gaap_ShareBasedCompensation 3,543us-gaap_ShareBasedCompensation 2,469us-gaap_ShareBasedCompensation
Depreciation 658us-gaap_Depreciation 370us-gaap_Depreciation 299us-gaap_Depreciation
Severance pay, net (55)cgen_SeverancePayNet 59cgen_SeverancePayNet 75cgen_SeverancePayNet
Gain from sale of Evogene shares (2,345)us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments (3,711)us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments   
Change in fair value of exchange option and embedded derivatives within research and development funding arrangements (269)us-gaap_UnrealizedGainLossOnDerivatives 811us-gaap_UnrealizedGainLossOnDerivatives 588us-gaap_UnrealizedGainLossOnDerivatives
Amortization of the Research and Development Component within research and development funding arrangement (337)cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement (230)cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement (130)cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement
Change in the fair value of liability with respect to outstanding options to non-employee    (104)us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities (20)us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities
Loss in respect to Termination and Equity Conversion Agreement 792cgen_GainLossInRespectToTerminationAndEquityConversionAgreement      
Decrease (increase) in other accounts receivable and prepaid expenses 1,026us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets (1,105)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets (112)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
Increase (decrease) in deferred revenues (4,983)us-gaap_IncreaseDecreaseInDeferredRevenue 6,772us-gaap_IncreaseDecreaseInDeferredRevenue   
Decrease (increase) in long-term prepaid expenses 152us-gaap_IncreaseDecreaseInPrepaidExpense 202us-gaap_IncreaseDecreaseInPrepaidExpense (301)us-gaap_IncreaseDecreaseInPrepaidExpense
Increase (decrease) in trade payables and other accounts payable and accrued expenses 1,674us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities 1,037us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities (86)us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
Net cash used in operating activities (11,148)us-gaap_NetCashProvidedByUsedInOperatingActivities (6,439)us-gaap_NetCashProvidedByUsedInOperatingActivities (10,846)us-gaap_NetCashProvidedByUsedInOperatingActivities
Cash flows from investing activities:      
Proceeds from maturity of short-term bank deposits 18,015us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments 3,215us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments 16,525us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments
Investment in short-term bank deposits (47,000)us-gaap_PaymentsToAcquireShortTermInvestments (18,015)us-gaap_PaymentsToAcquireShortTermInvestments (3,215)us-gaap_PaymentsToAcquireShortTermInvestments
Investment in long-term bank deposits (35,026)us-gaap_PaymentsToAcquireLongtermInvestments      
Changes in restricted cash (389)us-gaap_IncreaseDecreaseInRestrictedCash (50)us-gaap_IncreaseDecreaseInRestrictedCash   
Purchase of property and equipment (1,896)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (328)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (1,005)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Increase in long-term lease deposits (102)us-gaap_PaymentsForProceedsFromOtherInvestingActivities    (42)us-gaap_PaymentsForProceedsFromOtherInvestingActivities
Proceeds from sale of investment in Evogene 2,309us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities 3,603us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities   
Net cash provided by (used in) investing activities (64,089)us-gaap_NetCashProvidedByUsedInInvestingActivities (11,575)us-gaap_NetCashProvidedByUsedInInvestingActivities 12,263us-gaap_NetCashProvidedByUsedInInvestingActivities
Cash flows from financing activities:      
Proceeds from issuance of ordinary shares, net 70,718us-gaap_ProceedsFromIssuanceOfCommonStock 19,760us-gaap_ProceedsFromIssuanceOfCommonStock 6,211us-gaap_ProceedsFromIssuanceOfCommonStock
Proceeds from research and development funding arrangements    5,000cgen_ProceedsFromResearchAndDevelopmentFundingArrangements 1,000cgen_ProceedsFromResearchAndDevelopmentFundingArrangements
Proceeds from exercise of options 1,411us-gaap_ProceedsFromStockOptionsExercised 5,631us-gaap_ProceedsFromStockOptionsExercised 1,900us-gaap_ProceedsFromStockOptionsExercised
Net cash provided by financing activities 72,129us-gaap_NetCashProvidedByUsedInFinancingActivities 30,391us-gaap_NetCashProvidedByUsedInFinancingActivities 9,111us-gaap_NetCashProvidedByUsedInFinancingActivities
Increase (decrease) in cash and cash equivalents (3,108)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 12,377us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 10,528us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash and cash equivalents at the beginning of the year 28,751us-gaap_CashAndCashEquivalentsAtCarryingValue 16,374us-gaap_CashAndCashEquivalentsAtCarryingValue 5,846us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash and cash equivalents at the end of the year 25,643us-gaap_CashAndCashEquivalentsAtCarryingValue 28,751us-gaap_CashAndCashEquivalentsAtCarryingValue 16,374us-gaap_CashAndCashEquivalentsAtCarryingValue
Supplemental disclosure of non-cash investing and financing activities:      
Issuance of shares in respect to Termination and Equity Conversion Agreement 12,162cgen_IssuanceOfSharesInRespectToTerminationAndEquityConversionAgreement      
Receivables from foreign currency derivative contracts 141cgen_ReceivablesFromForeignCurrencyDerivativeContracts      
Receivables on account of shares 12cgen_ReceivablesOnAccountOfShares    56cgen_ReceivablesOnAccountOfShares
Purchase of property and equipment 284us-gaap_CapitalExpendituresIncurredButNotYetPaid    47us-gaap_CapitalExpendituresIncurredButNotYetPaid
Cash paid (received) during the year for:      
Income taxes 360us-gaap_IncomeTaxesPaidNet 500us-gaap_IncomeTaxesPaidNet   
Interest payments received from bank short-term deposits and cash equivalents $ (235)us-gaap_InterestPaid $ (112)us-gaap_InterestPaid $ (297)us-gaap_InterestPaid